X4 Pharmaceuticals, INC 10-Q quarterly reports

X4 Pharmaceuticals reports a significant decrease in revenue and an increased net loss for Q1 2026, primarily due to the cessation of substantial upfront license revenue recognized in the prior year.

X4 Pharmaceuticals reports Q3 2025 results, detailing a strategic shift to chronic neutropenia, significant workforce reductions, and successful capital raises totaling over $226 million.

X4 Pharmaceuticals reported a significant net loss in Q2 2025, driven by operating expenses and the absence of a prior year asset sale, while also raising substantial doubt about its ability to continue as a going concern.

X4 Pharmaceuticals announces Q1 2025 financial results, marked by revenue from the Norgine agreement and strategic restructuring efforts to focus on chronic neutropenia.

X4 Pharmaceuticals reports its Q3 2024 results, including initial revenue from XOLREMDI sales and continued progress in clinical trials for chronic neutropenia.

X4 Pharmaceuticals reports a net income of $90.8 million for the second quarter of 2024, primarily driven by a $105 million gain from the sale of a Priority Review Voucher.

X4 Pharmaceuticals' first quarter 2024 results show a significant net loss and raise concerns about the company's ability to continue as a going concern, despite the recent FDA approval of XOLREMDI.